What is the mechanism of action of the targeted therapy cabozantinib? How to choose the right patient group

Cabozantinib (Cabozantinib) is an oral small molecule multi-target tyrosine kinase inhibitor. Its mechanism of action regulates tumor growth, spread and angiogenesis by inhibiting multiple receptor tyrosine kinases. The main receptors targeted by cabozantinib include MET, VEGFR2, AXL, RET and KIT, etc. These receptors play an important role in the proliferation, survival and metastasis of tumor cells. By inhibiting these targets, cabozantinib can effectively reduce tumor angiogenesis, inhibit tumor cell proliferation, and enhance immune system response, thereby playing a role in the treatment of various cancers.

Cabozantinib has been approved to treat a variety of cancers, including advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and thyroid cancer. By inhibiting angiogenesis pathways such as MET and VEGFR2, cabozantinib can effectively reduce the blood supply of tumors, thereby inhibiting tumor growth. In addition, cabozantinib can also inhibit the invasion and metastasis of tumor cells by inhibiting receptors such as AXL, which is especially important for patients with advanced cancer. Therefore, cabozantinib exhibits important clinical value in tumor treatment, especially for drug-resistant or recurrent cancers.

Selection of the appropriate patient population is key to successful treatment with cabozantinib. Cabozantinib has been shown to have significant efficacy in patients with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Cabozantinib offers a new treatment option, especially in patients for whom traditional treatments, such as surgery or chemotherapy alone, are ineffective. When selecting patients, doctors typically consider how advanced the patient's disease is, the genetic characteristics of the tumor, and the patient's overall health. For some patients with hepatic or renal impairment, cabozantinib needs to be used with special caution to avoid exacerbating adverse reactions.

In addition, the therapeutic effects and side effects of cabozantinib are closely related, so patients need regular medical monitoring while receiving treatment. Due to the inhibitory effect of cabozantinib on multiple tyrosine kinases, it may cause some common adverse reactions, such as diarrhea, hypertension, loss of appetite, fatigue, etc. Therefore, when treating with cabozantinib, doctors typically conduct a detailed assessment of the patient's health to ensure the drug's maximum efficacy and minimal side effects. In addition, patients need to receive regular follow-up examinations so that treatment plans can be adjusted or supportive treatments can be adopted in a timely manner.

Reference:https://en.wikipedia.org/wiki/Cabozantinib

xa0